An interventional, randomized, double-blind, placebo-controlled, parallel-assignment, safety/efficacy study for treatment of chronic middle ear infection in adult patients with the antimicrobial peptide OP-145
Latest Information Update: 24 Feb 2019
Price :
$35 *
At a glance
- Drugs OP 145 (Primary)
- Indications Otitis media
- Focus Therapeutic Use
- Sponsors OctoPlus
- 21 Oct 2015 New source identified and integrated (ISRCTN - 12149720|).
- 12 Sep 2009 Results reported at ICAAC 2009.
- 28 Jul 2008 Complete and final study results are expected to be available by the end of 2008.